To investigate the dose-response relationship of semaglutide versus placebo and open-label liraglutide in terms of glycemic control in patients with type 2 diabetes.
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes / Nauck, Michael A; Petrie, John R; Sesti, Giorgio; Mannucci, Edoardo; Courrèges, Jean-Pierre; Lindegaard, Marie L; Jensen, Christine B; Atkin, Stephen L. - In: DIABETES CARE. - ISSN 1935-5548. - ELETTRONICO. - 39:(2016), pp. 231-241. [10.2337/dc15-0165]
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
MANNUCCI, EDOARDO;
2016
Abstract
To investigate the dose-response relationship of semaglutide versus placebo and open-label liraglutide in terms of glycemic control in patients with type 2 diabetes.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
231.full.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
1.3 MB
Formato
Adobe PDF
|
1.3 MB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.